A Study to Evaluate Immune Markers in Patients with Renal Cell Cancer
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 20-011522
NCT ID: NCT05112627
Sponsor Protocol Number: ROR2051
About this study
The objectives of this study are to measure baseline immune markers and peripheral blood mononuclear cell (PBMC) characteristics in RCC patients, to measure post-ablative therapy immune markers and PBMC characteristics, to compare effects of SBRT versus PCA on immune markers and PBMC characteristics, and to assess impact of post-treatment markers on time to disease progression and levels of markers at time of disease progression.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Histological diagnosis of primary RCC
- Histological or radiographic diagnosis of metastatic RCC
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-3
- Feasible vascular access as determined by study staff
- Undergoing standard of care SBRT or PCA to RCC metastatic lesion(s)
- Provide written informed consent
- Willing to consent to research blood draws
- Willing to return to enrolling institution for follow-up
Exclusion Criteria:
- Prior local treatment of the index metastatic lesion
- Pregnant or nursing women
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
of the investigator, would make the patient inappropriate for study entry
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Eligibility last updated 11/29/22. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator Bradley Stish, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available